TERPS Trial for de Novo Oligometastic Prostate Cancer

Inclusion Criteria11

• Patient must have at least one and up to three asymptomatic metastatic tumor(s) of the bone or soft tissue (with at least one bone metastasis) develop within the past 6-months that are seen on imaging. Up to five lesions are allowed on advanced functional imaging such as fluciclovine (Axumin), choline or PSMA PET-CT scan.
• CT or MRI scan within 6 months of enrollment
• Bone scan within 6 months of enrollment
• Fluciclovine (Axumin), choline, or PSMA PET-CT scan within 6 months of enrollment (PET-CT scan is reasonable for study entry imaging as an alternative to CT/MRI scan and bone scan)
• Histologic confirmation of malignancy (primary or metastatic tumor).
• Patient may have had prior systemic therapy and/or ADT associated with treatment within 9-months of enrollment.
• PSA \> 0.5 but \<100.
• Patient must be ≥ 18 years of age.
• Patient must have a life expectancy ≥ 12 months.
• Patient must have an ECOG performance status ≤ 2.
• Patient must have the ability to understand and the willingness to sign a written informed consent document